

VESTIBOLOGY

Benign paroxysmal positional vertigo: is hypothyroidism a risk factor for recurrence?

Vertigine parossistica posizionale benigna: l'ipotiroidismo è un fattore di rischio per la ricorrenza?

Laura Tricarico, Tiziana Di Cesare, Jacopo Galli, Anna Rita Fetoni, Gaetano Paludetti, Pasqualina Maria Picciotti
Fondazione Policlinico Universitario A. Gemelli IRCSS, Istituto di Otorinolaringoiatria, Roma - Università Cattolica del Sacro Cuore, Rome, Italy

SUMMARY

Objective. To investigate the relationship between risk of Benign Paroxysmal Positional Vertigo (BPPV) recurrence and hypothyroidism treated with hormone replacement therapy (HRT).

Methods. 797 patients with idiopathic BPPV were divided into two groups: 250 patients with recurrence of BPPV (R-BPPV) and 547 patients without recurrence (NR-BPPV). Regarding patients with thyroid disease on HRT, we collected serum test results of thyroid-stimulating hormone (TSH), free triiodothyronine f-T3, free thyroxine f-T4, thyroglobulin antibodies (TG-Ab) and thyroid peroxidase antibodies (TPO-Ab).

Results. Hypothyroidism in long-term HRT was found in 61/250 (24.4%) patients of the R-BPPV group vs 79/547 (14.4%) of the NR-BPPV-group ($p = 0.0006$). Hashimoto thyroiditis (HT) was associated with recurrence ($p < 0.0001$). A significant correlation was found between recurrence and level of serum TPO-Ab ($p = 0.0117$) and TG-Ab ($p = 0.0025$), but not with mean serum TSH, f-T3 and f-T4.

Conclusions. We assume that patients with hypothyroidism in HRT have an increased risk of BPPV recurrence, which is particularly strong for patients with HT and positive thyroid antibodies, suggesting an association between autoimmunity and recurrent vertigo.

KEY WORDS: BPPV, recurrence vertigo, hypothyroidism, thyroid autoimmunity, vertigo comorbidities

RIASSUNTO

Obiettivo. Analisi dell'associazione tra la ricorrenza della Vertigine parossistica posizionale benigna (BPPV) e l'ipotiroidismo in corso di terapia ormonale sostitutiva (TOS).

Metodi. 797 pazienti affetti da BPPV idiopatica sono stati suddivisi in due gruppi: 250 con vertigine ricorrente (R-BPPV) e 547 (NR-BPPV) non ricorrente. Nei pazienti ipotiroidici sono stati analizzati i valori ematici tiroidei: ormone tireotropo (TSH), frazioni libere di tetraiodotironina (f-T4) e triiodotironina (f-T3), anticorpi anti tireoperossidasi (TPO-Ab) ed anti tireoglobulina (TG-Ab).

Risultati. L'ipotiroidismo è emerso in 61/250 (24,4%) pazienti del gruppo R-BPPV vs 79/547 (14,4%) del gruppo NR - BPPV ($p = 0,0006$). La ricorrenza è risultata statisticamente associata alla tiroidite di Hashimoto (HT) ($p < 0,0001$) ed alla positività anticorpale di Ab-TPO ($p = 0,0117$) e Ab-TG ($p = 0,0025$); le concentrazioni sieriche medie di TSH, f-T3 e f-T4 non sono risultate statisticamente significative.

Conclusioni. Nei pazienti affetti da ipotiroidismo in TOS è stato dimostrato un aumentato rischio di ricorrenza di BPPV, particolarmente evidente nei pazienti con HT e dosaggio anticorpale tiroideo positivo, suggerendo l'associazione tra autoimmunità e ricorrenza della vertigine.

PAROLE CHIAVE: vertigine parossistica posizionale benigna (VPPB), vertigine ricorrente, ipotiroidismo, autoimmunità tiroidea, comorbidità nella VPPB

Received: July 25, 2021
Accepted: September 27, 2021
Published online: February 7, 2022

Correspondence

Laura Tricarico
Fondazione Policlinico Universitario A. Gemelli IRCSS, Clinica di Otorinolaringoiatria; Università Cattolica del Sacro Cuore
largo A. Gemelli 1, 00168 Rome, Italy
E-mail: lauratricarico90bis@gmail.com

How to cite this article: Tricarico L, Di Cesare T, Galli J, et al. Benign paroxysmal positional vertigo: is hypothyroidism a risk factor for recurrence? Acta Otorhinolaryngol Ital 2022;42:465-470. <https://doi.org/10.14639/0392-100X-N1775>

© Società Italiana di Otorinolaringoiatria e Chirurgia Cervico-Facciale



OPEN ACCESS

This is an open access article distributed in accordance with the CC-BY-NC-ND (Creative Commons Attribution-Non-Commercial-NoDerivatives 4.0 International) license. The article can be used by giving appropriate credit and mentioning the license, but only for non-commercial purposes and only in the original version. For further information: <https://creativecommons.org/licenses/by-nc-nd/4.0/deed.en>

Introduction

Hypothyroidism is one of the most common disorders of the endocrine system. It can refer to insufficient synthesis of thyroxine (T4) and triiodothyronine (T3), released into the bloodstream in response to stimulation by pituitary thyroid stimulating hormone (TSH), or to the dysfunction of hormone-free biologically active forms (f-T3, f-T4) related to peripheral receptors¹. The prevalence of hypothyroidism is approximately 1-3% in Western general population². In iodine sufficient areas of the world, the most frequent cause of hypothyroidism is chronic autoimmune thyroiditis, also known as Hashimoto's thyroiditis (HT). Hypothyroidism is also common following radioiodine treatment, hemithyroidectomy or total thyroidectomy, and neck radiation or surgery for cancer therapy. Furthermore, suboptimal iodine status can result in goitre, thyroid nodules and hypothyroidism¹. Thyroid hormone replacement with levothyroxine is the standard treatment for patients with hypothyroidism³. The most typical clinical manifestations of hypothyroidism include fatigue, lethargy, bradycardia, weight gain and cold intolerance, but it has also been recently associated with ENT disorders, such as hearing loss⁴, tinnitus⁵ and vestibular disorders⁶. Among the different vestibular pathologies, the association between hypothyroidism and benign paroxysmal positional vertigo (BPPV) has recently been investigated⁷. BPPV is the most common peripheral vestibular disease accounting for approximately 17-42% of diagnoses of dizziness in specialised clinics. It can be described as a sudden and abnormal sensation of motion and/or rotational vertigo, lasting less than one minute, accompanied by characteristic nystagmus. In this disorder, otoliths detach from the utricle and enter in the semicircular canals to cause vertigo⁸. Symptoms are triggered by positional changes of the head and can range from mild dizziness to debilitating episodes that may induce nausea or vomiting.

BPPV can be classified as primary or idiopathic (50-70%) and secondary to trauma or viral infections, Meniere's disease, migraine, otologic and non-otologic surgery, and prolonged bed rest⁹. In idiopathic cases, no apparent cause of BPPV is identified in the patient's history. Most episodes of BPPV, even if untreated, recover spontaneously in 2 to 6 weeks¹⁰. However, clinical resolution is more often obtained by executing one of more manoeuvres in 50-70% of cases¹¹. Later recurrences of BPPV are common. Choi et al. defined recurrent BPPV as the reappearance of positional nystagmus after at least 2 weeks from the execution of repositioning manoeuvres¹².

Previous papers by our group^{13,14} and other authors¹⁵ showed that risk of recurrence increases for patients with a comorbidity compared to healthy patients, and multiple

associated diseases further increase the risk of recurrence of idiopathic BPPV. Among the associated pathologies, hypothyroidism and its autoimmune pathogenesis has gained increasing emphasis, but there are still few studies investigating the relationship between thyroid function or pathology and BPPV pathogenesis or recurrence. Moreover, not all studies on the topic have consistent results and large-scale clinical trials to clarify the associations are needed¹⁶. The aim of this study was to investigate the relationship between hypothyroidism, thyroid autoimmunity and BPPV recurrence by measurement of thyroid hormones and serum thyroid autoantibodies.

Materials and methods

Patients consecutively referred to the Vestibular Service, in the day clinic, reporting vertigo and diagnosed with idiopathic BPPV, were recruited for the study. We collected data on 797 patients aged from 12 to 87 years (mean 62.5 ± 14.3 years): 506 females (63.5%) and 291 males (36.5%). We retrospectively divided all patients in two groups: non-recurrent BPPV (NR-BPPV), reporting first occurrence of vertigo, and recurrent (R-BPPV) defined as the reappearance of positional nystagmus after at least 2 weeks from its resolution¹². We excluded patients with previous head trauma, whiplash injuries, or "persistent" BPPV, namely no remission of symptoms or nystagmus after 2 weeks or 5 repositioning manoeuvres. We excluded patients with hyperthyroidism and/or thyroid eye-related disease from the study.

All patients were evaluated based on accurate clinical history and bedside-examination by an experienced examiner. Posterior canal (PC)-BPPV was diagnosed in case of geotropic torsional nystagmus with specific latency, frequency, duration and "reduction effect" (nystagmus reduction after repetition of the manoeuvre) by the Dix-Hallpike or Semont manoeuvre. On the other hand, horizontal canal (HC)-BPPV diagnosis was based on the observation of horizontal direction-changing positional nystagmus with the McClure-Pagnini manoeuvre. We treated patients with specific repositioning manoeuvres and reassessed them after 7 days, until the resolution of symptoms and nystagmus disappeared. In case of recurrence of symptoms, patients were re-evaluated in the day clinic and treated again.

Previous histories of hypothyroidism on hormone replacement therapy (HRT), such as autoimmune thyroiditis, goitre and thyroidectomy, were investigated in both the R-BPPV and NR-BPPV groups. We collected laboratory data on TSH (normal values: 0.35-2.80 µIU/mL), f-T3 (n.v. 2.3-4.2 pg/ml), f-T4 (n.v. 8.5-15.5 pg/ml), Thyroglobulin antibodies TG-Ab (n.v. < 4.1 IU/ml) and thyroid peroxidase antibodies TPO-Ab (n.v. < 5.6 IU/ml).

In accordance with AACE/ATA guidelines¹⁷, we considered mild or subclinical hypothyroidism patients with TSH concentrations above the reference range with f-T3 and f-T4 concentrations within normal range; overt or clinical hypothyroidism high TSH with f-T4 and/or f-T3 concentrations below the reference range. Autoimmunity pattern was defined in the presence of serum antibody titres (TG-Ab and/or TPO-Ab) above the reference range.

We analysed the clinical characteristics of BPPV (number of recurrences, canal involved, number and type of manoeuvres, duration of therapy) to establish possible differences in patients with thyroid disease compared to other idiopathic BPPV patients. Moreover, data were evaluated statistically in order to establish the relationship between BPPV recurrence and thyroid disease in patients taking hormone replacement therapy, and the risk of recurrence in both subclinical/overt hypothyroidism related to different etiopathogeneses.

Statistical analysis was performed using commercially available software (Excel—Microsoft Corporation, Redmond, Washington, USA). Continuously distributed data were summarised as the mean and median, and categorical variables with frequencies and percentages. The χ^2 test and odds ratios (OR) with 95% confidence intervals were used for non-parametric variables; Student t-test was performed for parametric variables. A p value less than 0.05 was considered as significant.

Results

The group of non-recurrent (NR-BPPV) consisted of 547/797 (68.6%) patients, whereas 250/797 (31.4%) had recurrent vertigo (R-BPPV) (Tab. I).

140/797 (17.6%) patients suffered from hypothyroidism treated with HRT. In detail, 61/250 (24.4%) patients with R-BPPV vs 79/547 (14.4%) with NR-BPPV reporting a history of thyroid dysfunction. Thyroid disease requiring HRT, regardless of aetiology, can be considered a risk factor for recurrence vertigo ($p = 0.0006$, OR = 1.92) (Tab. I).

Laboratory evaluation of thyroid gland functional activity showed that in the R-BPPV group, 22/250 (8.8%) patients had hypothyroidism: 10/22 with a subclinical pattern and 12/22 with overt hypothyroidism. In the NR-BPPV group, 21/549 (3.8%) subjects showed hypothyroidism, of whom 6/21 had subclinical and 15/21 overt. Statistical analysis showed that hypothyroidism was more frequently encountered in the group of recurrent BPPV ($p = 0.0039$, OR = 3.01), although a significant association was present only with subclinical hypothyroidism ($p = 0.0067$, OR = 3.76) and not with overt hypothyroidism ($p > 0.05$) (Tab. I). Mean serum TSH, free-T3 and free-T4 concentrations, on the other hand, were not significantly different between the two groups ($p > 0.05$) (Tab. II).

Previous history of thyroid disorders such as goitre, hypothyroidism and autoimmune thyroiditis was investigated in both the R-BPPV and NR-BPPV groups. In relation to the

Table I. Thyroid functional pattern.

	R-BPPV n = 250	NR-BPPV n = 547	p value	OR
History of thyroid dysfunction in HRT	61 (24.4%)	79 (14.4%)	0.0006	1.92
Patients with altered thyroid hormones	22 (8.8%)	21 (3.8%)	0.0039	3.01
Subclinical hypothyroidism	10 (4%)	6 (1%)	0.0067	3.76
Overt hypothyroidism	12 (4.8%)	15 (2.7%)	> 0.05	
Autoimmunity	49 (19.6%)	35 (6.4%)	< 0.0001	3.57

Comparison between recurrent benign paroxysmal positional vertigo (R-BPPV) and non-recurrent (NR-BPPV). Statistical significance was set at $p < 0.05$. HRT: hormone replacement therapy; BPPV: benign paroxysmal positional vertigo.

Table II. Laboratory testing in thyroid disorders.

Laboratory	R-BPPV n = 61	NR-BPPV n = 79	p value
TSH (n.v. 0.35-2.80 μ IU/ml)	1.8 \pm 0.9	1.4 \pm 0.9	> 0.05
f-T3 (n.v. 2.3-4.2 pg/ml)	2.9 \pm 0.6	2.5 \pm 0.4	> 0.05
f-T4 (n.v. 8.5-15.5 pg/ml)	10.8 \pm 4.3	8.8 \pm 2.6	> 0.05
TPO-Ab (n.v. < 5.6 IU/ml)	249.6 \pm 393	107.1 \pm 213.8	0.0117
TG-Ab (n.v. < 4.1 IU/ml)	132.1 \pm 162	22.3 \pm 54.3	0.0025

Hormonal dosages and thyroid autoantibodies: comparison between the two groups of BPPV patients suffering from thyroid diseases. Statistical significance was set at $p < 0.05$. TSH: thyroid stimulating hormone; f-T3: triiodothyronine; f-T4: free thyroxine; TG-Ab: Thyroglobulin antibodies; TPO-Ab: thyroid peroxidase antibodies; BPPV: benign paroxysmal positional vertigo; R-BPPV: recurrent BPPV; NR-BPPV: non-recurrent BPPV.

different causes of hypothyroidism, an autoimmune pathogenesis was detected in 84/140 (60%) patients: 49/250 (19.6%) R-BPPV vs 35/547 (6.4%) NR-BPPV (Tab. I). The association between autoimmune chronic thyroiditis pattern and BPPV recurrence was significant ($p < 0.0001$, OR = 3.57). In particular, the presence of high antibody serum titres increased the risk of recurrence by 3.57 times (Table I), and mean TPO-Ab and TG-Ab levels were significantly higher in the R-BPPV group ($p = 0.0117$) (Tab. II). Multinodular goitre was the cause of HRT in 22.4% (31/140) of cases: 6/250 (2.4%) with R-BPPV and 25/574 (4.3%) with NR-BPPV, with no significant difference ($p > 0.05$). In all, 17.8% (25/140) of patients were taking HRT following total thyroidectomy: 9/250 (3.6%) in the group of R-BPPV and 16/574 (2.7%) in NR-BPPV, with no significant difference ($p > 0.05$) (Fig. 1).

Clinical characteristics of BPPV in patients with thyroid dysfunction are reported in Table III: the affected ear was the right one in 76/140 (54.3%) patients and the left in 60/140 (42.8%); 4/140 patients (2.8%) had bilateral disease. The canal involved was posterior in 127/140 (90.7%) and horizontal in 13/140 (9.3%); 69.2% had the apogeotropic type and 30.8% the geotropic type. Multicanalar involvement occurred in 9/140 patients (6.4%) with a double involvement of horizontal and posterior canals, in one or both inner ears. The analysis of clinical management of T-BPPV patients showed that this group required a mean of 1.9 ± 1.5 manoeuvres. In 86/140 (61.5%) patients, resolution was achieved with a single manoeuvre, while 54/140 (38%) needed more than one manoeuvre. Comparison between thyroid dysfunctional BPPV and other idiopathic BPPV patients showed that the posterior semicircular canal was more involved in the first group with a significant difference ($p = 0.0087$). There was no difference as to side involved and prognosis, or mean number of manoeuvres,

resolution rate after one manoeuvre and multicanalar involvement (Tab. III).

Discussion

This retrospective analysis, performed on a large sample of idiopathic BPPV patients, showed that 17.6% (140/797) had hypothyroidism and were undergoing long-term treatment with HRT. Papi et al. described a similar prevalence result in a multicentre case-control study with a percentage of 21% in the BPPV group¹⁸. In literature, the relationship between thyroid disease and inner ear dysfunction has been attributed to abnormal thyroid functioning resulting in changes of the endolymphatic ionic composition of the labyrinth, through altered expression of ion transporters such as sodium iodide symporter (NIS) and pendrin¹⁹, identified both in the inner ear and thyroid. It has been suggested that the volume or compositional changes of the endolymph of the vestibular labyrinth can induce BPPV²⁰. Therefore, reduced levels of thyroid hormones were also related to cardiovascular compromise, endothelial dysfunction and changes in blood pressure, thus reducing blood flow in the inner ear²¹. The combination of the aforementioned pathogenic mechanisms can bring about the absorption or precipitation of otoconial debris, inducing BPPV⁷.

Similarly, we can hypothesise that altered thyroid function may be somewhat related to the recurrence of BPPV. From our results, clinical history for hypothyroidism on treatment with HRT was significantly ($p = 0.0006$) more frequent in patients with R-BPPV (61/250; 24.4%) than in NR-BPPV (79/547; 14.4%). This result underscores that a history of hypothyroidism, on its own, represents a risk factor for development of the recurrence of BPPV, regardless of its aetiopathogenesis.

Nevertheless, considering laboratory examination for thyroid function, no certain association was found between TSH, f-T4 and/or f-T3 levels and recurrence, since only subclinical hypothyroidism showed an increased risk of R-BPPV (OR = 3.76). Conversely, we did not find a significantly positive association between recurrence and overt hypothyroidism. Furthermore, the mean values of f-T3, f-T4 and TSH were not significantly different between the two groups (R-BPPV and NR-BPPV), showing that reduced levels of hormones in the bloodstream alone does not influence the clinical course of benign positional vertigo. In line with these results, Chiarella et al. showed a significant correlation between vestibular disease and serum TPO-Ab but not with TSH²², hypothesising that the association between vestibular lesions and HT was not influenced by the thyroid functional status.

Among different causes of hypothyroidism, chronic au-




Figure 1. Percentage distribution of NR-BPPV and R-BPPV patients based on different causes of hypothyroidism. *: statistical significance.

Table III. Clinical characteristics of study patients.

BPPV tot.	Thyroid dysfunctional BPPV	Other BPPV	P value
N = 797	N = 140	N = 657	
Bilateral	4 (2.8%)	8 (1.2%)	> 0.05
Side affected	Right: 76 (54.3%) Left: 60 (42.8%)	Right: 363 (55.2%) Left: 286 (43.5%)	> 0.05
Posterior canal	127 (90.7%)	536 (81.6%)	0.0087
Horizontal canal	13 (9.3%) Apogeotropic: 9/13 (69.2%) Geotropic: 4/13 (30.8%)	121 (18.4%) Apogeotropic: 66/121 (54.5%) Geotropic: 55/121 (45.4%)	0.0087
No. manoeuvres	1.9 ± 1.5	1.8 ± 1.3	> 0.05
Single episode resolution after 1 manoeuvre	86 (61.5%)	401 (61%)	> 0.05
Multicanalar Involvement	9 (6.4%)	39 (5.9%)	> 0.05

Comparison between patients with thyroid dysfunctional BPPV and patients with other type of idiopathic BPPV. Statistical significance was set at $p < 0.05$. BPPV: benign paroxysmal positional vertigo.

toimmune thyroiditis or HT was reported as the most frequent thyroid disease in our sample, and its prevalence was higher among R-BVVP (49/250; 19.6%) patients compared to NR-BVVP (35/547; 6.4%) with a significant difference between the two groups. TPO-Ab and TG-Ab are the most common HT autoantibodies identified and are associated with complement-mediated cytotoxicity against thyrocytes²³.

Further interesting data emerged concerning the antibody dosage of the recruited patients with a diagnosis of HT. Both antibody titres were increased in patients with recurrence compared to the NR-BVVP group: mean TPO-Ab titre was 249.6 vs 107 IU/ml, while mean TG-Ab titre was 132.1 IU/ml vs 22.3 IU/ml. This result confirms the evidence of a positive linkage between thyroid antibodies and vestibular disease as previously demonstrated by Papi et al.¹⁸: these authors showed that the association of BPPV with elevated anti-thyroid antibodies (OR 25.6) was stronger than the association of BPPV with hypothyroidism (OR 12.9). Moreover, the same group of authors found BPPV in 18% of patients affected by HT and normal thyroid hormonal pattern, compared to 2% of healthy control subjects²⁴. Modugno et al.²⁵ also hypothesised autoimmune alterations in patients with BPPV: they discovered autoimmune alterations in 48.5%, with a major level of anti-thyroid antibodies in 27.1%, without other 'risk factors'. The authors postulated a link between HT and vestibular disease, possibly related to mechanical stimulation by immune complexes and possible co-existence of microangiitis in the inner ear. Our experience on recurrent BPPV and thyroid autoimmunity could be related to this hypothesis, with a tendency of vertigo not to heal quickly, compared with other types of idiopathic BPPV. On the other hand, patients with non-autoimmune hypothyroidism, such as post-thyroidectomy or multinodular goitre, had no increased risk of recurrence,

suggesting that autoimmune pathogenesis can overload the clinical course of vertigo. In contrast with our results, Sari et al.¹⁶ found that thyroid autoantibody levels in subjects with BPPV did not significantly differ from those in patients with other vestibular diseases and in normal subjects, taking into account that further large-scale studies should be done to clarify the relation.

Regarding the clinical characteristics of BPPV in patients with thyroid dysfunction, the posterior semicircular canal was most frequently involved compared to other idiopathic patients ($p = 0.0087$). We can hypothesise that the posterior canal can be more easily damaged by a terminal vascularisation ensured by the posterior vestibular artery, since there is a longer distance from the main internal auditory artery without collateral pathway, compared to the horizontal canal. In case of cardiovascular impairment due to hypothyroidism, this mechanism could be exacerbated.

Conclusions

The present study revealed an increased risk of recurrence of BPPV in patients with a history of hypothyroidism on HRT; the association is particularly strong for patients with positive thyroid antibodies dosage. TPO-Ab and TG-Ab levels were significantly higher in the R-BPPV group, demonstrating an association between autoimmunity and recurrence. Therefore, in complete evaluation of recurrent BPPV, we suggest investigating thyroid dysfunction by studying not only TSH, fT3 and fT4, but also the autoantibody thyroid pattern. Finally, a multidisciplinary approach and collaboration between the ENT and endocrinologist specialists is desirable.

Conflict of interest statement

The authors declare no conflict of interest.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Authors' contributions

All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by LT, TDC, MPP. LT wrote the first draft of the manuscript and others authors commented on previous versions of the manuscript.

Ethical consideration

The study protocol was approved by the local Ethics Committee (44075/2018).

The research was conducted ethically, with all study procedures being performed in accordance with the requirements of the World Medical Association's Declaration of Helsinki.

Written informed consent was obtained from all participants included in the study.

References

- Chaker L, Bianco AC, Jonklaas J, et al. Hypothyroidism. *Lancet* 2017;390:1550-1562. [https://doi.org/10.1016/S0140-6736\(17\)30703-1](https://doi.org/10.1016/S0140-6736(17)30703-1)
- Giorda CB, Carnà P, Romeo F, et al. Prevalence, incidence and associated comorbidities of treated hypothyroidism: an update from a European population. *Eur J Endocrinol* 2017;176:533-542. <https://doi.org/10.1530/EJE-16-0559>
- Koulouri O, Auldin MA, Agarwal R, et al. Diagnosis and treatment of hypothyroidism in TSH deficiency compared to primary thyroid disease: pituitary patients are at risk of under-replacement with levothyroxine. *Clin Endocrinol (Oxf)* 2011;74:744-749. <https://doi.org/10.1111/j.1365-2265.2011.03984.x>
- Mortensen AH, Fang Q, Fleming MT, et al. Genetic variation in thyroid folliculogenesis influences susceptibility to hypothyroidism-induced hearing impairment. *Mamm Genome* 2019;30:5-22. <https://doi.org/10.1007/s00335-019-09792-6>
- Kim SY, Min C, Kim HJ, et al. Low thyroid-stimulating hormone levels are associated with annoying tinnitus in adult women: Korea National Health and Nutrition Examination Surveys. *Otol Neurotol* 2021;42:e408-e415. <https://doi.org/10.1097/MAO.0000000000003030>
- Chiarella G, Russo D, Monzani F, et al. Hashimoto thyroiditis and vestibular dysfunction. *Endocr Pract* 2017;23:863-868. <https://doi.org/10.4158/EP161635.RA>
- Choi HG, Song YS, Wee JH, et al. Analyses of the relation between BPPV and thyroid diseases: a nested case-control study. *Diagnostics (Basel)* 2021;11:329. <https://doi.org/10.3390/diagnostics11020329>
- Kim JS, Zee DS. Clinical practice. Benign paroxysmal positional vertigo. *N Engl J Med* 2014;370:1138-1147. <https://doi.org/10.1056/NEJMc1309481>
- Pérez P, Franco V, Cuesta P, et al. Recurrence of benign paroxysmal positional vertigo. *Otol Neurotol* 2012;33:437-443. <https://doi.org/10.1097/MAO.0b013e3182487f78>
- Zucca G, Valli S, Valli P, et al. Why do benign paroxysmal positional vertigo episodes recover spontaneously? *J Vestib Res* 1998;8:325-329.
- Brandt T, Huppert D, Hecht J, et al. Benign paroxysmal positioning vertigo: a long-term follow-up (6-17 years) of 125 patients. *Acta Otolaryngol* 2006;126:160-163. <https://doi.org/10.1080/00016480500280140>
- Choi SJ, Lee JB, Lim HJ, et al. Clinical features of recurrent or persistent benign paroxysmal positional vertigo. *Otolaryngol Head Neck Surg* 2012;147:919-924. <https://doi.org/10.1177/0194599812454642>. Corrigendum. *Otolaryngol Head Neck Surg* 2013;149:798. <https://doi.org/10.1177/0194599813505840>
- Picciotti PM, Lucidi D, De Corso E, et al. Comorbidities and recurrence of benign paroxysmal positional vertigo: personal experience. *Int J Audiol* 2016;55:279-284. <https://doi.org/10.3109/14992027.2016.1143981>
- Picciotti PM, Di Cesare T, Tricarico L, et al. Is drug consumption correlated with benign paroxysmal positional vertigo (BPPV) recurrence? *Eur Arch Otorhinolaryngol* 2020;277:1609-1616. <https://doi.org/10.1007/s00405-020-05855-6>
- Messina A, Casani AP, Manfrin M, et al. Italian survey on benign paroxysmal positional vertigo. Survey italiana sulla vertigine parossistica posizionale. *Acta Otorhinolaryngol Ital* 2017;37:328-335. <https://doi.org/10.14639/0392-100X-1121>
- Sari K, Yildirim T, Borekci H, et al. The relationship between benign paroxysmal positional vertigo and thyroid autoimmunity. *Acta Otolaryngol* 2015;135:754-757. <https://doi.org/10.3109/00016489.2015.1021932>
- Garber JR, Cobin RH, Gharib H, et al. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association *Thyroid* 2012;22:1200-1235. <https://doi.org/10.1089/thy.2012.0205>. Erratum in: *Thyroid*. 2013;23:251. Erratum in: *Thyroid*. 2013;23:129
- Papi G, Corsello SM, Milite MT, et al. Association between benign paroxysmal positional vertigo and autoimmune chronic thyroiditis. *Clin Endocrinol (Oxf)* 2009;70:169-170. <https://doi.org/10.1111/j.1365-2265.2008.03311.x>
- Mian C, Lacroix L, Alzieu L, et al. Sodium iodide symporter and pendrin expression in human thyroid tissues. *Thyroid* 2001;11:825-830. <https://doi.org/10.1089/105072501316973073>
- Manzari L. Enlarged vestibular aqueduct (EVA) related with recurrent benign paroxysmal positional vertigo (BPPV). *Med Hypotheses* 2008;70:61-65. <https://doi.org/10.1016/j.mehy.2007.04.032>
- Jabbar A, Pingitore A, Pearce SH, et al. Thyroid hormones and cardiovascular disease. *Nat Rev Cardiol* 2017;14:39-55. <https://doi.org/10.1038/nrcardio.2016.174>
- Chiarella G, Tognini S, Nacci A, et al. Vestibular disorders in euthyroid patients with Hashimoto's thyroiditis: role of thyroid autoimmunity. *Clin Endocrinol (Oxf)* 2014;81:600-605. <https://doi.org/10.1111/cen.12471>
- Blanchin S, Estienne V, Durand-Gorde JM, et al. Complement activation by direct C4 binding to thyroperoxidase in Hashimoto's thyroiditis. *Endocrinology* 2003;144:5422-5429. <https://doi.org/10.1210/en.2003-0918>
- Papi G, Guidetti G, Corsello SM, et al. The association between benign paroxysmal positional vertigo and autoimmune chronic thyroiditis is not related to thyroid status. *Thyroid* 2010;20:237-238. <https://doi.org/10.1089/thy.2009.0319>
- Modugno GC, Pirodda A, Ferri GG, et al. A relationship between autoimmune thyroiditis and benign paroxysmal positional vertigo? *Med Hypotheses* 2000;54:614-615. <https://doi.org/10.1054/mehy.1999.0905>